Chronic low-grade fever or fever with mild lymphadenopathy may indicate Castleman disease if no malignant, autoimmune, or infectious cause of the lymphadenopathy is identified

Czech version

Authors: prof. MUDr. Adam Zdeněk, CSc. ¹; MUDr. Kamarádová Kateřina, Ph.D. ²; doc. MUDr. Doubková Martina, Ph.D. ³; doc. MUDr. Řehák Zdeněk, Ph.D. ⁴; MUDr. Koukalová Renata, Ph.D. ⁴; MUDr. Křivanová Andrea, Ph.D. ¹; doc. MUDr. Horváth Teodor, Ph.D. ⁵; MUDr. Čermák Aleš, Ph.D. ⁶; MUDr. Boichuk Ivanna ¹; MUDr. Štork Martin, Ph.D. ¹; MUDr. Sandecká Viera, Ph.D. ¹; MUDr. Adamová Zuzana, Ph.D. ⁷; prof. MUDr. Pour Luděk, Ph.D. ¹
Authors‘ workplace: Interní hematologická a onkologická klinika LF MU a FN Brno ¹; Fingerlandův ústav patologie, LF UK v Hradci Králové ²; Klinika nemocí plicních a tuberkulózy LF MU a FN Brno ³; Oddělení nukleární medicíny, MOU Brno ⁴; Chirurgická klinika LF MU a FN Brno ⁵; Urologická klinika LF MU a FN Brno ⁶; Chirurgické oddělení, Moravskoslezská nemocnice Frýdek-Místek ⁷
Published in: Klin Onkol 2026; 39(3): 169-183
Category: Review
doi: https://doi.org/10.48095/ccko2026169

Overview

Background: Diseases caused by immune system disorders fall under the care of every medical specialty. In hematology, these are diseases caused by autoantibodies, several autoinflammatory diseases (Schnitzler syndrome and VEXAS syndrome), as well as immune disorder-induced diseases presenting with systemic inflammatory reactions and lymphadenopathy. In the5^th edition of the WHO classification, these diseases are categorized under the chapter “Tumour-like lesions with B-cell predominance”, which includes Castleman disease (CD). Objective: This paper provides an overview of information on CD from the perspective of the years 2025 and 2026. In patients with unicentric CD (UCD), associations with paraneoplastic pemphigus or obliterative bronchiolitis have been described in rare cases. Prognostically unfavorable is the transformation of UCD into a follicular dendritic cell sarcoma. In cases of multicentric CD (MCD), the etiology is exceptionally identified as an infection with human herpesvirus 8. In rare cases of MCD combined with POEMS syndrome, the etiology is considered to be a monoclonal gammopathy. In most cases of MCD, none of the aforementioned etiologies are demonstrated, and these forms of MCD are referred to as idiopathic MCD (iMCD). The most aggressive form of iMCD is called iMCD-TAFRO, and its course resembles a cytokine storm. The form with the lowest aggressiveness was defined recently –⁠ idiopathic plasmacytic lymphadenopathy (iMCD-IPL) with a high concentration of polyclonal immunoglobulins and a higher concentration of the IgG4 subclass of immunoglobulins. Between these two extreme forms lies the majority of cases falling into the iMCD-NOS (not otherwise specified) category. Differences in the aggressiveness are caused by differences in etiopathogenesis. The text presents recent criteria for these diseases, information on symptoms, diagnosis, and prognosis. Conclusion: In MCD, suspicion must be raised in individuals with a systemic inflammatory response and lymphadenopathy after ruling out autoimmune, malignant, and infectious etiologies. Diagnosis of CD is clinico-pathological, meaning it arises based on the exchange of information between the clinician, who must suspect the disease, and the pathologist, who examines the histomorphological findings while taking into account the information provided by the clinicians.

Keywords:

Castleman disease

Sources

1. Adam Z, Mayer J, Pour L et al. Autoinflamatorní choroby se symptomy, které připomínají maligní krevní choroby –⁠ syndrom Schnitzlerové, Stillova choroba dospělých, SAPHO a VEXAS syndrom. Transfuze Hematol dnes 2024; 30 (3): 151–168. doi: 10.48095/cctahd2024prolekare.cz13.

2. Alaggio R, Amador C, Anagnostopoulos I et al. The5^th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 2022; 36 (7): 1720–1748. doi: 10.1038/s41375-022-01620-2.

3. Schmalzing M, Sander O, Seidl M et al. Castleman’s disease in the rheumatological practice. Z Rheumatol 2024; 83 (Suppl 3): 289–298. doi: 10.1007/s00393-024-01560-5.

4. Petersdorf RG, Beeson PB. Fever of unexplained origin: report on 100 cases. Medicine (Baltimore) 1961; 40 : 1–30. doi: 10.1097/00005792-196102000-00001.

5. Knockaert DC, Vanderschueren S, Blockmans D. Fever of unknown origin in adults: 40 years on. J Intern Med 2003; 253 (3): 263–275. doi: 10.1046/j.1365-2796.2003.01120.x.

6. Romano Gargarella E, Vocaturo F, Guarneri A et al. Role of 18F FDG-PET-CT in fever and inflammation of unknown origin. J Clin Med 2025; 14 (16): 5861. doi: 10.3390/jcm14165861.

7. Řehák Z, Šprláková-Puková A, Kazda T et al. ¹⁸F-FDG PET/CT in polymyalgia rheumatica-a pictorial review. Br J Radiol 2017; 90 (1076): 20170198. doi: 10.1259/bjr.20170198.

8. Pierson SK, Bagg A, Alapat D et al. Characterization of Castleman disease reveals patients with oligocentric adenopathy and clinicopathologic characteristics similar to unicentric Castleman disease. Blood 2021; 138 (Suppl 1): 1622. doi: 10.1182/blood-2021-153840.

9. Pierson SK, Brandstadter JD, Torigian DA et al. Characterizing the heterogeneity of castleman disease and oligocentric subtype: findings from the ACCELERATE registry. Blood Adv 2025; 9 (8): 1952–1965. doi: 10.1182/bloodadvances.2024014391.

10. Beckham TH, Yang JC, Chau KW et al. Excellent outcomes with surgery or radiotherapy in the management of castleman disease including a case of oligocentric disease. Clin Lymphoma Myeloma Leuk 2020; 20 (10): 685–689. doi: 10.1016/j.clml.2020.05.002.

11. Zhang L, Liu QH, Zhou H et al. Asymptomatic multicentric castleman disease: a potential early stage of idiopathic MCD. Blood Adv 2024; 8 (21): 5598–5602. doi: 10.1182/bloodadvances.2024013728.

12. Smith D, Eichinger A, Fennell É et al. Spatial and single cell mapping of Castleman disease reveals key stromal cell types and cytokine pathways. Nat Commun 2025; 16 (1): 6009. doi: 10.1038/s41467-025-61214-1.

13. van Rhee F, Oksenhendler E, Srkalovic G et al. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Adv 2020; 4 (23): 6039–6050. doi: 10.1182/bloodadvances.2020003334.

14. Horváth T, Frola L, Adam Z et al. Léčba unicentrické Castlemanovy choroby rituximabem, bendamustinem a dexametazonem zmenšila objem expanzivního ložiska v horním mediastinu a umožnila jeho radikální odstranění. Klin Onkol 2025; 38 (2): 132–143. doi: 10.48095/ccko2025132.

15. Penka I, Kala Z, Zetelová A. et al. Casteman disease –⁠ surgical treatment, case reports. Rozhl Chir 2016; 95 (12): 457–461.

16. Dunn R, Jariwal R, Venter F et al. HHV-8-associated multicentric Castleman disease, a diagnostic challenge in a patient with acquired immunodeficiency syndrome and fever. J Investig Med High Impact Case Rep 2022; 10 : 23247096221097526. doi: 10.1177/23247096221097526.

17. Osa M, Maeda T, Misawa K et al. Clinical response to liposomal doxorubicin and rituximab in HHV-8-associated multicentric Castleman’s disease in an HIV-positive patient. J Infect Chemother 2016; 22 (12): 804–807. doi: 10.1016/j.jiac.2016.06.004.

18. Kaga H, Kurahashi H, Kubota A et al. Successful rituximab treatment of an elderly Japanese patient with HHV8--positive, HIV-negative multicentric castleman disease. Int J Hematol 2022; 115 (1): 129–134. doi: 10.1007/s12185-021-03222-7.

19. Murphy C, Hawkes E, Chionh F et al. Durable remission of both multicentric Castleman’s disease and Kaposi’s sarcoma with valganciclovir, rituximab and liposomal doxorubicin in an HHV-8-positive, HIV-negative patient. J Clin Pharm Ther 2017; 42 (1): 111–114. doi: 10.1111/jcpt.12472.

20. Min C, Liu A, Xu Y et al. A case report of Castleman disease variant of POEMS syndrome presenting with prominent polyserositis and renal impairment. Front Med (Lausanne) 2025; 12 : 1537944. doi: 10.3389/fmed.2025.1537944.

21. Brioli A, Wyrwa A, Rüddel U et al. Mutations in the plasma cell clone identify mechanism of polyneuropathy in a case of POEMS syndrome associated with Castleman disease and multiple myeloma. Ann Hematol 2023; 102 (1): 239–242. doi: 10.1007/s00277-022-05032-1.

22. Lee YM, Choi YS, Kim JM. POEMS syndrome: presented as idiopathic multicentric Castleman disease of plasma cell variant for eight years and dramatic treatment with siltuximab followed by autologous peripheral blood stem cell transplantation. Diagnostics (Basel) 2022; 12 (4): 998. doi: 10.3390/diagnostics12040998.

23. Minařík J, Ščudla V, Bačovský J et al. POEMS syndrom. Onkologie (Olomouc) 2011; 5 (3): 151–154.

24. Ji M, Jin S, Zang S et al. Castleman disease variant of POEMS syndrome without M protein: a case report. Front Oncol 2024; 14 : 1449945. doi: 10.3389/fonc.2024.1449945.

25. Prokop J, Estorninho J, Marote S et al. POEMS syndrome: a rare cause of adrenal insufficiency in a young male. Endocrinol Diabetes Metab Case Rep 2019; 2019: EDM190010. doi: 10.1530/EDM-19-0010.

26. Fajgenbaum DC. The cytokine storm of multicentric Castleman disease. Adv Exp Med Biol 2024; 1448 : 459–467. doi: 10.1007/978-3-031-59815-9_31.

27. Zhou QY. Castleman disease and TAFRO syndrome: to improve the diagnostic consciousness is the key. World J Clin Cases 2022; 10 (5): 1536–1547. doi: 10.12998/wjcc.v10.i5.1536.

28. Godfrey K, Harris E, Moss H et al. Idiopathic multicentric castleman disease of TAFRO subtype. Br J Haematol 2022; 196 (3): 461. doi: 10.1111/bjh.17843.

29. Takai K. TAFRO syndrome: a syndrome or a subtype of multicentric Castleman disease? Biomedicines 2024; 12 (3): 652. doi: 10.3390/biomedicines12030652.

30. Nishimura Y, Nishimura MF, Fajgenbaum DC et al. Global public awareness of Castleman disease and TAFRO syndrome between 2015 and 2021: a google trends analysis. EJHaem 2022; 3 (3): 748–753. doi: 10.1002/jha2.459.

31. Lossos C, Brown J, Sheikhbahaei S et al. Idiopathic multicentric Castleman disease –⁠ TAFRO results in high levels of mtor activator SVEP1, tissue factor, and endotheliopathy. Blood Vessel Thromb Hemost 2024; 1 (2): 100006. doi: 10.1016/j.bvth.2024.100006.

32. Lust H, Gong S, Remiker A et al. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: a pediatric case series. Pediatr Blood Cancer 2021; 68 (10): e29261. doi: 10.1002/pbc.29261.

33. Nishimura Y, Hanayama Y, Fujii N et al. Comparison of the clinical characteristics of TAFRO syndrome and idiopathic multicentric Castleman disease in general internal medicine: a 6-year retrospective study. Intern Med J 2020; 50 (2): 184–191. doi: 10.1111/imj.14404.

34. Gao YH, Liu YT, Zhang MY et al. Idiopathic multicentric Castleman disease (iMCD) -idiopathic plasmacytic lymphadenopathy: a distinct subtype of iMCD-not otherwise specified with different clinical features and better survival. Br J Haematol 2024; 204 (5): 1830–1837. doi: 10.1111/bjh.19334.

35. Nishikori A, Nishimura MF, Fajgenbaum DC et al. Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): factors to differentiate from IgG4-related disease. J Clin Pathol 2025; 79 (1): 43–49. doi: 10.1136/jcp-2023-209280.

36. Nishikori A, Nishimura MF, Nishimura Y et al. Idiopathic plasmacytic lymphadenopathy forms an independent subtype of idiopathic multicentric Castleman disease. Int J Mol Sci 2022; 23 (18): 10301. doi: 10.3390/ijms231810301.

37. Yen CC, Chen TY. Idiopathic plasmacytic lymphadenopathy with polyclonal hypergammaglobinemia mimicking plasma cell myeloma. Blood 2018; 132 (25): 2700. doi: 10.1182/blood-2018-07-863290.

38. Kojima M, Nakamura N, Otuski Y et al. Pulmonary lesion of idiopathic plasmacytic lymphadenopathy with polyclonal hyperimmunoglobulinemia appears to be a cause of lymphoplasmacytic proliferation of the lung: a report of five cases. Pathol Res Pract 2008; 204 (3): 185–190. doi: 10.1016/j.prp.2007.11.003.

39. Tartakover Matalon S, Rabinowicz N, Carmi O et al. Examination of the level of circulating plasmablasts and their characteristics as diagnostic tools for immunoglobulin G4-related disease. Isr Med Assoc J 2024; 26 (6): 369–375.

40. Chen LYC, Zhang L, Fajgenbaum DC. Expert perspective: diagnosis and treatment of Castleman disease. Arthritis Rheumatol 2026; 78 (1): 12–25. doi: 10.1002/art.43269.

41. Munshi N, Mehra M, van de Velde H et al. Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk Lymphoma 2015; 56 (5): 1252–1260. doi: 10.3109/10428194.2014.953145.

42. Mukherjee S, Martin R, Sande B et al. Epidemiology and treatment patterns of idiopathic multicentric castleman disease in the era of IL-6-directed therapy. Blood Adv 2022; 6 (2): 359–367. doi: 10.1182/bloodadvances.2021004441.

43. Hoffmann C, Oksenhendler E, Littler S et al. The clinical picture of Castleman disease: a systematic review and meta-analysis. Blood Adv 2024; 8 (18): 4924–4935. doi: 10.1182/bloodadvances.2024013548.

44. Feng A, Gonzalez MV, Kalaycioglu M et al. Common connective tissue disorder and anti-cytokine autoantibodies are enriched in idiopathic multicentric Castleman disease patients. Front Immunol 2025; 16 : 1528465. doi: 10.3389/fimmu.2025.1528465.

45. Nakazato Y, Tsuchida S, Takada-Owada A et al. Castleman disease and mimickers: clinicopathological findings of atypical lymphoproliferative disorders associated with autoimmune disease. J Clin Exp Hematop 2022; 62 (3): 119–126. doi: 10.3960/jslrt.22025.

46. Kaegi C, Wuest B, Schreiner J et al. Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders. Front Immunol 2019; 10 : 1990. doi: 10.3389/fimmu.2019.01990.

47. Cáceres Medina JL, González Torres LA, Gamboa--Meza A et al. Rituximab as a first-line treatment for autoimmune hemolytic anemia in multicentric Castleman’s disease. Cureus 2024; 16 (4): e59080. doi: 10.7759/cureus.59080.

48. Iskandar A, Hwang A, Dasanu CA. Severe warm-antibody autoimmune hemolytic anemia due to multicentric castleman disease: responding to rituximab. J Oncol Pharm Pract 2019; 25 (8): 2016–2018. doi: 10.1177/1078155218816775.

49. Plano F, Mancuso S, Camarda GM et al. A multicentric Castleman disease associated with mixed warm and cold antibody-mediated AHA responsive to siltuximab. Chemotherapy 2024; 69 (1): 35–39. doi: 10.1159/000533235.

50. Qian Y, Zhang M. Retinal vasculitis associated with Castleman disease. JAMA Ophthalmol 2025; 143 (1): e245152. doi: 10.1001/jamaophthalmol.2024.5152.

51. Rössler M, Kiessling B, Klotz JM et al. Recurrent cerebral ischemias due to cerebral vasculitis within the framework of incomplete POEMS syndrome with Castleman disease. Nervenarzt 2004; 75 (8): 790–794. doi: 10.1007/s00115-004-1683-x.

52. Yin H, Zhang L, Pan B et al. Cerebral thrombotic event as a rare complication in a young female patient with idiopathic multicentric Castleman disease. Clin Neurol Neurosurg 2020; 198 : 106246. doi: 10.1016/j.clineuro.2020.106246.

53. Goda T, Oyama N, Iwamoto T et al. A case of cerebral infarction in a patient with TAFRO syndrome. J Neurol Sci 2019; 400 : 21–22. doi: 10.1016/j.jns.2019.03.006.

54. Jakubíková M, Piťha J, Latta J et al. Myasthenia gravis, Castleman disease, pemphigus, and anti-phospholipid syndrome. Muscle Nerve 2013; 47 (3): 447–451. doi: 10.1002/mus.23657.

55. Pan Y, Cui Z, Wang S et al. Idiopathic multicentric Castleman disease with Sjögren’s syndrome and secondary membranous nephropathy: a case report and review of the literature. BMC Nephrol 2020; 21 (1): 528. doi: 10.1186/s12882-020-02191-z.

56. Nandy S, Bhattacharya D, Kundu S et al. Myasthenia gravis with Castleman disease: a case report with review of literature. Indian J Pathol Microbiol 2025; 68 (2): 392–394. doi: 10.4103/ijpm.ijpm_482_23.

57. Kim HJ, Han JH, Bang CH et al. Cutaneous disorders associated with Castleman’s disease. Acta Derm Venereol 2019; 99 (11): 984–989. doi: 10.2340/00015555-3253.

58. González García A, Fernández-Martín J, Robles Marhuenda Á. Idiopathic multicentric castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis. Rheumatology (Oxford) 2023; 62 (4): 1426–1435. doi: 10.1093/rheumatology/keac481.

59. Dispenzieri A, Armitage JO, Loe MJ. et al. The clinical spectrum of Castleman’s disease. Amer J Hematol 2012; 87 (11): 997–1002. doi: 10.1002/ajh.23291.

60. Fajgenbaum DC, Uldrick TS, Bagg A et al. International, evidence-based consensus diagnostic criteria for HHV--8-negative/idiopathic multicentric Castleman disease. Blood 2017; 129 (12): 1646–1657. doi: 10.1182/blood-2016-10-746933.

61. Gasljevic G, Bonometti A, Anagnostopoulos I et al. The morphological spectrum of Castleman disease and related disorders: a report from the lymphoma workshop of the 22nd meeting of the European Association of Hematopathology. Virchows Arch 2025; 487 (2): 253–273. doi: 10.1007/s00428-025-04171-w.

62. Nishimura MF, Haratake T, Nishimura Y et al. International consensus histopathological criteria for subtyping idiopathic multicentric Castleman disease based on machine learning analysis. Am J Hematol 2025; 100 (9): 1502–1512. doi: 10.1002/ajh.27743.

63. van Rhee F, Voorhees P, Dispenzieri A et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 2018; 132 (20): 2115–2124. doi: 10.1182/blood-2018-07-862334.

64. Nishimura Y, Fajgenbaum DC, Pierson SK et al. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. Am J Hematol 2021; 96 (10): 1241–1252. doi: 10.1002/ajh.26292.

65. Alnoor F, Spies NC, Kumar J et al. The evolution and recent advances in diagnostic criteria for idiopathic multicentric Castleman disease. Am J Hematol 2025; 100 (11): 2064–2073. doi: 10.1002/ajh.70039.

66. Li SY, Gao YH, Dang Y et al. TAFRO Syndrome without pathology supporting Castleman disease: to be treated as idiopathic multicentric Castleman disease-tafro or a distinct disease entity? Turk J Haematol 2025; 42 (1): 1–8. doi: 10.4274/tjh.galenos.2025.2024.0420.

67. Wang G, Xu Q, Liu Y et al. 18F-FDG PET/CT Metabolic parameters are correlated with clinical features and valuable in clinical stratification management in patients of Castleman disease. Cancer Imaging 2025; 25 (1): 12. doi: 10.1186/s40644-025-00833-9.

68. Iguchi T, Nishikori A, Sato Y et al. Computed tomography findings of idiopathic multicentric Castleman disease subtypes. J Clin Exp Hematop 2024; 64 (4): 292–296. doi: 10.3960/jslrt.24053.

69. Koukalová R, Selingerová I, Řehák Z et al. FDF-PET/CT v diagnostice a hodnocení léčebné odpovědi, retrospektivní studie 29 případů z jednoho centra. Klin Onkol 2021; 34 (2): 120–127. doi: 10.48095/ccko2021120.

70. Cui Z, Zhou X, Luo F et al. Worldwide bronchiolitis obliterans research: a bibliometric analysis of the published literature between 2002 and 2022. Medicine (Baltimore) 2023; 102 (28): e34263. doi: 10.1097/MD.0000000000034263.

71. Bartková H, Válková V, Vydra J et al. Bronchiolitis obliterans syndrom jako projev chronické reakce štěpu proti hostiteli po allogenní transplantaci krvetvorných buněk. Stud Pneumol Phthiseol 2021; 81 (3): 112–120.

72. Lau HX, Krebs L, Sim S et al. Lymphoid interstitial pneumonia without known cause: diagnostic work up and differential considerations. Respirol Case Rep 2025; 13 (4): e70175. doi: 10.1002/rcr2.70175.

73. Doubková M, Doubek M, Richter S et al. Běžná variabilní imunodeficience a granulomatózní/lymfocytární intersticiální plicní nemoc (GLILD). Stud Pneumol Phthiseol 2023; 83 (5): 159–169.

74. Dispenzieri A, Gertz MA, Therneau TM et al. Retrospective cohort study of 148 patients with polyclonal gammopathy. Mayo Clin Proc 2001; 76 (5): 476–487. doi: 10.4065/76.5.476.

75. Zhao EJ, Carruthers MN, Li CH et al. Conditions associated with polyclonal hypergammaglobulinemia in the IgG4-related disease era: a retrospective study from a hematology tertiary care center. Haematologica 2020; 105 (3): e121–e123. doi: 10.3324/haematol.2019.219725.

76. Andre M, Contis A, Berard AM. Etiological study of polyclonal hypergammaglobulinemia in a French cohort of hospitalized patients and proposal of a diagnostic aid algorithm: short title: polyclonal hypergammaglobulinemia in a French cohort of hospitalized patients. Sci Rep 2024; 14 (1): 31282. doi: 10.1038/s41598-024-82735-7.

77. Beuvon C, Martin M, Baillou C et al. Etiologies of polyclonal hypergammaglobulinemia: a scoping review. Eur J Intern Med 2021; 90 : 119–121. doi: 10.1016/j.ejim.2021.05.023.

78. Sasaki T, Akiyama M, Kaneko Y et al. Immunoglobulin G4-related disease and idiopathic multicentric Castleman’s disease: confusable immune-mediated disorders. Rheumatology (Oxford) 2022; 61 (2): 490–501. doi: 10.1093/rheumatology/keab634.

79. Sun C, Xu G, Lin J. Comparison of IgG4-Related lymphadenopathy and multicentric Castleman’s disease: a retrospective study. Clin Lab 2018; 64 (10): 1671–1678. doi: 10.7754/Clin.Lab.2018.180421.

80. Izumi Y, Takeshita H, Moriwaki Y et al. Multicentric Castleman disease mimicking IgG4-related disease: a case report. Mod Rheumatol 2017; 27 (1): 174–177. doi: 10.3109/14397595.2014.985356.

81. Yoshimi R, Nakajima H. Idiopathic multicentric Castleman’s disease as a Mimicker of IgG4-related disease. Intern Med 2025; 64 (12): 1788–1790. doi: 10.2169/internalmedicine.4793-24.

82. Qin Y, Shang L, Wang Y et al. Immune profile differences between IgG4-related diseases and primary Sjögren’s syndrome. J Inflamm Res 2025; 18 : 911–923. doi: 10.2147/JIR.S471266.

83. Otani Y, Shimura T, Nogaki T et al. Differentiation between IgG4-related Mikulicz disease and Sjögren’s syndrome: a review case report and literature review. Medicine (Baltimore) 2022; 101 (52): e32617. doi: 10.1097/MD.0000000000032617.

84. Yu L, Shi M, Cai Q et al. A novel predictive model for idiopathic multicentric Castleman disease: the international Castleman disease consortium study. Oncologist 2020; 25 (11): 963–973. doi: 10.1634/theoncologist.2019-0986.

85. Covelli C, Carosi I, Graziano P et al. When idiopathic retroperitoneal fibrosis mimics Castleman disease: a challenging differential diagnosis. BMJ Case Rep 2022; 15 (4): e248051. doi: 10.1136/bcr-2021-248051.

86. Fichtl J, Třeška V, Vodička J et al. Castlemanova choroba –⁠ neobvyklý nález při operaci tumoru retroperitonea u mladého nemocného. Rozhl Chir 2016; 95 (2): 91–94.

87. Szturz P, Plank L, Křístek J et al. Castlemanova choroba v obrazech. Postgrad Med 2014; 16 (1): 81–88.

88. Kazakov DV, Fanburg-Smith JC, Szster S et al. Castleman disease of the subcutis and underlying skeletal mucle: report of 6 cases. Am J Surg Pathol 2004; 28 (5): 569–577. doi: 10.1097/00000478-200405000-00002.

89. Moláček J, Treska V, Skalický V. et al. Unicentric form of Castleman’s disease, pitfalls of diagnosis and surgical treatment. Front Oncol 2023; 13 : 1057683. doi: 10.3389/fonc.2023.1057683.

90. Škach J, Vytiska J, Gaalová R et al. Castlemanova choroba imitující tumor perikardu. Kazuistiky v alergologii, pneumologii a ORL 2014; 11 (1): 3–7.

91. Čéška F, Ferko A, Jon B et al. Pancreatic Castleman disease treated with laparoscopic distal pancreatectomy. Hepatobiliary Pancreat Dis Int 2013; 12 (3): 332–334. doi: 10.1016/s1499-3872 (13) 60053-3.

92. Zavázalová Š, Jirák P, Syrůček M et al. Castlemanova choroba –⁠ mimicking a malignant lymphoma. Otorinolaryngol Foniatr 2014; 63 (4): 246–250.

93. Kazakov D, Morisson C, Plaza JA et al. Sarcoma arising in hyaline-vascular Castleman disease of skin and subcutis. Am J Dermatopathol 2005; 27 (4): 327–332. doi: 10.1097/01.dad.0000171606.55810.86.

94. Cibičková L, Soukup T, Bradna P. et al. Asociace revmatoidní artritidy a Castlemanovy choroby. Čes Revmatol 2005; 3 (3): 106–109.

95. Camprt V. Monitor aneb nemělo by vám uniknout, že už se ví, jak diagnostikovat idiopatickou multicentrickou Castlemanovu chorobu. Čes-slov Patol 2023; 59 (3): 89–95.

96. Ciferská H, Vachek J. Uzlinové syndromy –⁠ zaměřeno na Castlemanovu chorobu. Medicína po promoci 2021; 22 (3): 222–231.

97. Kufa J, Novotná J Lukášovíá M. et al. Raritní granulomatózní procesy. Transfuze Hematol Dnes 2024; 30 (2): 122–130. doi: 10.48095/cctahd2024prolekare.cz11.

98. Jakubíková M. Autoimunitní onemocnění periferního nervového svstému. Generalizovaná forma myasthenia gravis a jiné autoimunity na společném imunopatogenetickém pozadí interleukinu-6. Autoimunity nervového systému v kazuistikách II. 1. vyd. Praha: EEZY Publishing, s.r.o 2023 : 143–149.

99. Adam Z, Řehák Z, Boichuk I et al. Léčba Castlemanovy choroby z pohledu roku 2026. Klin Onkol 2026; 39 (2): 86–98. doi: 10.48095/ccko202686.